Cue Biopharma (NASDAQ: CUE) awards 24,400 stock options to director

Rhea-AI Filing Summary

Cue Biopharma director Sarraf Pasha reported receiving a stock option award from the company. On 01/02/2026, Pasha was granted an option to buy 24,400 shares of Cue Biopharma common stock at an exercise price of $0.34 per share, with no cash paid for the grant itself. The award was made under the company’s Director Compensation Policy.

The filing states that this option becomes fully exercisable on the first anniversary of the grant date and carries an expiration date of 01/01/2036. Following this grant, Pasha beneficially owns 24,400 derivative securities in the form of these stock options, held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sarraf Pasha

(Last) (First) (Middle)

C/O CUE BIOPHARMA, INC.

40 GUEST STREET

(Street)

BOSTON MA 02135

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cue Biopharma, Inc. [ CUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.34	01/02/2026		A		24,400(1)		(2)	01/01/2036	Common Stock	24,400	$0.0	24,400	D

Explanation of Responses:

1. Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy.

2. This stock option becomes fully exercisable on the first anniversary of the grant date.

	/s/ Pasha Sarraf by Colin Sandercock, attorney-in-fact	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Cue Biopharma (CUE) report for Sarraf Pasha?

The filing reports that director Sarraf Pasha received a grant of 24,400 stock options to purchase Cue Biopharma common stock.

What are the key terms of Sarraf Pasha’s Cue Biopharma stock option grant?

Pasha’s option covers 24,400 shares of common stock at an exercise price of $0.34 per share, granted on 01/02/2026 and expiring on 01/01/2036.

When do Sarraf Pasha’s Cue Biopharma options vest?

The filing states that this stock option becomes fully exercisable on the first anniversary of the grant date, which is one year after 01/02/2026.

Is this Cue Biopharma Form 4 a grant or a sale of shares?

The Form 4 reports an acquisition of derivative securities (transaction code A) in the form of a stock option grant, not a sale of existing shares.

How many Cue Biopharma derivative securities does Sarraf Pasha own after this transaction?

After this reported transaction, Pasha beneficially owns 24,400 derivative securities, all from this stock option grant, held directly.

Under what policy was Sarraf Pasha’s Cue Biopharma option granted?

The footnotes explain that the award represents a stock option granted pursuant to Cue Biopharma’s Director Compensation Policy.

Does Sarraf Pasha’s stock option grant involve any special entities or indirect ownership?

The filing shows the options as held directly (D) by Sarraf Pasha, with no nature of indirect beneficial ownership disclosed.